Perosphere Pharmaceuticals Inc clinical trials
Acquired by Azurity Pharmaceuticals, Mar 14, 2025 · source ↗
The registry lists 11 studies whose lead sponsor is Perosphere Pharmaceuticals Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 2, 2025.
Before and after it joined Azurity Pharmaceuticals
- First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- 11
- First submitted after Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.11 studies
Something wrong with this grouping? Tell us on the Azurity Pharmaceuticals page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Azurity Pharmaceuticals studies →
- Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCTCompletedNCT03172910Phase 2
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCTCompletedNCT03288454Phase 2
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes MellitusWithdrawnNCT02206568Phase 1
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of EdoxabanCompletedNCT01826266Phase 1
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With EdoxabanCompletedNCT02207257Phase 2
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- PK and PD of Single, Escalating Doses of PER977 Following EnoxaparinCompletedNCT02206100Phase 1/2
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following HeparinCompletedNCT02206087Phase 1/2
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With AnticoagulantsCompletedNCT03296982
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time MeasurementsCompletedNCT02205827Not applicable
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male SubjectsCompletedNCT02205905Phase 1
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals
- Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct VenipunctureCompletedNCT02207205Not applicable
Sponsor listed in the registry: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. · First submitted before Perosphere Pharmaceuticals Inc became part of Azurity Pharmaceuticals